Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
|NCT03307785||Ib||Advanced solid tumors||Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer||View Drugs||Arizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas|
|Niraparib||MK4827, Zejula||PARP inhibitor|
|Bevacizumab||immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin||VEGF antagonist|
|Carboplatin||Paraplatin, Novoplatinum||DNA damaging agent|
|Paclitaxel||Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL||Microtubule stabilizer/mitotic inhibitor|
|TSR-022||Blocks TIM-3 inhibition of T cells|
|TSR-042||anti-PD-1 monoclonal antibody TSR-042, ANB011, Dostarlimab||Blocks PD-L1/2 inhibition of T cells|